2013-02-27 08:33:43 - Japan’s cancer mAbs market is likely to post double-digit growth to reach US$ 2.7 Billion by 2015, says RNCOS in its latest research report.
As per RNCOS’s new research report entitled, “Cancer Monoclonal Antibodies Market to 2015”, cancer represents a major concern area and cause for high direct healthcare expenditures. Amongst the various cancers, colorectal cancer consumes the largest share of resources. The Japanese mAbs market is still largely untapped and is characterized by a slow approval process and delayed marketing authorization. It is expected that in the future, authorities will take optimum measures to popular cancer mAbs among the population due to the specificity that they offer over traditional therapy. Overall, the market for cancer mAbs in Japan is likely to advance at a CAGR of around 15% during 2012-2015 to reach US$ 2.7 Billion.
Further, our research has found that four drugs currently
dominate the global antineoplastics mAbs market, including Roche’s Avastin (Bevacizumab), MabThera (Rituximab), and Herceptin (Trastuzumab); and BMS/Merck’s Erbitux. The report has also identified that among the several drug classes for cancer treatment, antineoplastics mAbs are the leading category driven by factors, such as fast increase in the number of new cancer cases and the emergence of innovative technologies. As the prevalence of cancer and mortality rate continues to rise worldwide, the healthcare community started focusing on mAbs as an effective treatment option over chemotherapy. This, in turn, has boosted the revenue patterns of private players engaged in the market.
The report investigates and analyzes all the key developments of cancer mAbs’ market throughout the world. It also identifies the possible growth areas in terms of pipeline products and provides an in-depth analysis on the leading drugs under development with reference to their manufacturers and other key details. Exhaustive research on country-level analysis of cancer mAbs market is also covered along with a broad overview of current developments. The report, which is an outcome of prudent analysis and extensive research on the antineoplastic mAbs market, is spread in over 100 pages. Future forecasts for the overall industry and key sections/areas on the basis of past trends, challenges, opportunities for expansion along with economic and judgmental analysis are also provided in the report. Further, the report illustrates about the approved mAbs, along with their recent industry developments to provide a balanced outlook on the potentials of the growing market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM375.htm
Some of our Related Reports are:
- Indian Healthcare - New Avenues for Growth (http://www.rncos.com/Report/IM151.htm)
- Insulin Delivery Systems Market Forecast to 2014 (http://www.rncos.com/Report/IM369.htm)
- Global Genetic Testing Market Analysis (http://www.rncos.com/Report/IM352.htm)
- US Diagnostic Market Outlook 2014 (http://www.rncos.com/Report/IM298.htm)
- Global In Vitro Diagnostic Market Analysis (http://www.rncos.com/Report/IM103.htm)
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.